Celcuity Inc. (CELC) stock fell 22.41 percent to $95.41, losing $27.55 on Tuesday, despite announcing detailed positive efficacy data from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial for gedatolisib.
The stock is currently trading at $95.41, compared to its previous close of $122.96 on the Nasdaq. During the session, it reached a high of $99.83 and a low of $94.32, with trading volume climbing to 1,383,663 shares, notably higher than its average daily volume of 938,892.
The sell-off occurred as the clinical-stage biotechnology company prepared to present late-breaking data on its breast cancer treatment candidate at the American Society of Clinical Oncology (ASCO) Annual Meeting. Though the study demonstrated that the gedatolisib-triplet nearly doubled median progression-free survival (PFS) to 11.1 months compared to 5.6 months for the control arm.
Celcuity Inc.'s 52-week range is $11.09 to $151.02.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.